Mass High TechBiogen Idec Q1 revenues up 7 percentMass High Tech… has announced that its first-quarter revenues for the three months ending on March 31 were $1.3 billion, up 7 percent from the same time a year before, due largely to increased sales o…
UK patients to be barred from first new lupus drug in 50 yearsPharma TimesIn addition, some patients with severe disease currently receive rituximab off-label. Although it is not licensed for this use, the Committee would have liked to see data compari…
Bay News 9Priority Health: RA treatmentBay News 9Abatacept is available as both an infusion and a self-injection, as noted above. Infliximab is given during a two-hour procedure every two to eight weeks. Rituximab is given over several hours. You may r…
Clinical Oncology NewsFludarabine Plus Rituximab Assessed in Relapsed/Refractory HCLClinical Oncology NewsA team of researchers from Vancouver, British Columbia, has found that treatment with combination therapy of fludarabine (Fludara, Genzyme; variou…
Plant-Made Pharmaceuticals And The Democratization Of Health CareSeeking AlphaThe Ibiolaunch has successfully expressed both humanized and chimeric monoclonal antibodies, Paviluzumab and Rituximab, respectfully. Astrazeneca (AZN), parent of MedImmune, …
OncLiveEmerging Markers Point to Future Strategies in CLL: An Interview With William …OncLivePlease discuss your research into fludarabine, cyclophosphamide, and rituximab (FCR)-based treatment for CLL. 1 Assume you have a patient who has developed a…
Gilead Sciences Management Discusses Q1 2012 Results – Earnings Call TranscriptSeeking AlphaAs a final R&D highlight, 3 Phase III studies will be initiated in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL, which is 1101 …
The GuardianDrug company attacks Nice for rejecting new lupus treatmentThe GuardianThe standard treatment usually consists of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and/or immunosuppressants such as rituximab in some cases. Ar…
Clinical Oncology NewsAdjuvant Radiation After R-CHOP-14 Increases Lymphoma SurvivalClinical Oncology NewsWhile the addition of rituximab had clearly contributed to increased response rates, event-free survival and OS in PMLBCL, the role of radiotherap…
Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter …MarketWatch (press release)Conduct the "ZAR" trial, a head-to-head study vs. rituximab maintenance in follicular non-hodgkin's lymphoma in North America Spe…